Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation

Transplant Proc. 1996 Apr;28(2):913-4.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunosuppression Therapy*
  • Kidney Neoplasms / immunology*
  • Male
  • Mice
  • Middle Aged
  • Prospective Studies
  • Receptors, Interleukin-2 / immunology
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins